Shelter Pharma FY26: Growth Accelerates, Margins Ease

Revenue from operations was INR 73.13 crore in FY26 and net profit (PAT) was INR 9.03 crore, as per the presentation.

Revenue from operations increased from INR 50.66 crore in FY25 to INR 73.13 crore in FY26, a 44.35% YoY increase.

EBITDA margin declined to 17.39% in FY26 from 19.88% in FY25, and net margin declined to 12.35% from 14.29%.

The company operates in human healthcare and veterinary (animal) healthcare, with products across ayurvedic, herbal, OTC and nutraceutical categories.

The presentation states a target of INR 200 crore in annual revenues by 2030, supported by capacity expansion, new launches and global penetration.

The company states it has acquired land near Himatnagar, Gujarat for a second manufacturing facility to enhance production capacity, but it does not disclose capex amount or commissioning timeline.

The presentation lists Bangladesh, UAE, Iraq, Yemen, Egypt, Kuwait, Sudan and UK, and also mentions approvals/registration in Nepal, Egypt, Kuwait and Bhutan.